NCT00471315

Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)

Pilot Study of the Efficacy and Tolerability of Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction).

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Open-label single center study of duloxetine in patients with SOD who have failed to respond to the standard treatments. This protocol is designed to explore the tolerability and efficacy of Duloxetine in the management of patients with known or suspected Sphincter of Oddi dysfunction (SOD).

Detailed description

SOD is a disorder involving the bile duct or pancreas causing a burning pain or cramping in the epigastric (upper stomach) area that can radiate (spread) to the back or under the right shoulder blade. This discomfort is thought to be caused by tightening of the Sphincter of Oddi, which is the muscle opening that controls the flow of bile and juices from the pancreas (enzymes) into the small intestine. It can also be caused by contractions of the common bile duct (the duct that allows bile from the liver into the small intestine). The purpose of this research is to study how well a medication called Duloxetine works when used to treat pain associated with SOD. Duloxetine (also called Cymbalta) is a medication approved by the FDA for the treatment of depression and for the treatment of pain caused by nerve damage associated with diabetes. However, for the purposes of this research, Duloxetine is considered investigational (experimental) since it will test how well this medication works for the treatment of pain associated with SOD. (Cymbalta replaced with Duloxetine in remainder of consent as requested). PRIMARY OBJECTIVE ● Treatment effect as measured by the global assessment of change (PGIC) after 3 months of treatment with duloxetine. SECONDARY OBJECTIVES * Toleration of the medication as measured by the duloxetine compliance rate; * Safety as recorded by adverse events (AEs) * Effect of treatment on pain reduction as measured by a pain burden assessment tool (RAPID 3 \& RAPID 1-Month); * Effect of treatment on quality of life (QOL) as measured by the SF-36.

Conditions

• Sphincter of Oddi Dysfunction

Interventions

Type	Name	Description
DRUG	Duloxetine	A preliminary, open-label single center study of duloxetine in patients with SOD

Timeline

• Start date: 2006-07-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2007-05-09
• Last updated: 2014-02-06
• Results posted: 2014-02-06

Locations

1 site across 1 country: United States